WITCHA VIPUDHAMORN

Dr. WITCHA VIPUDHAMORN


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in Annals of Coloproctology
Verified
Journal Article
Open access
WVWITCHA VIPUDHAMORN
WITCHA VIPUDHAMORN
TJTawan Juthasilaparut
Tawan Juthasilaparut
PSPawit Sutharat
Pawit Sutharat
SSSuwan Sanmee
Suwan Sanmee
ESEkkarin Supatrakul
Ekkarin Supatrakul
RRRujee Rattanasathien
Rujee Rattanasathien
Sclerosing encapsulating peritonitis (SEP) is a rare but serious condition characterized by the progressive formation of a dense fibrous sheath encasing the small bowel within the peritoneal cavity. This review provides a comprehensive overview of the current understanding of SEP, focusing on its etiology, clinical presentation, diagnostic modalities, and management strategies. SEP can be classified into primary and secondary forms, each with distinct etiologies and treatment approaches. Primary SEP typically presents with acute or subacute bowel obstruction symptoms, necessitating surgical intervention to excise the fibrous sheath and relieve the obstruction. Secondary SEP often occurs in patients undergoing peritoneal dialysis, with cessation of dialysis being a key component of management. Medical treatments, including corticosteroids, immunosuppressive agents, and nutritional support, may complement surgical intervention, particularly in cases of secondary SEP. Advanced imaging techniques and personalized medicine approaches show promise in improving diagnostic accuracy and tailoring treatment strategies to individual patients. Future research directions include investigating targeted pharmacological therapies, exploring minimally invasive surgical techniques, and conducting long-term follow-up studies to evaluate treatment efficacy and disease recurrence. Multidisciplinary care teams play a crucial role in the comprehensive management of SEP, emphasizing collaboration among various specialties to optimize patient outcomes.

27 March 2024 in World Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
WVWITCHA VIPUDHAMORN
WITCHA VIPUDHAMORN
TJTawan Juthasilaparut
Tawan Juthasilaparut
PSPawit Sutharat
Pawit Sutharat
SSSuwan Sanmee
Suwan Sanmee
ESEkkarin Supatrakul
Ekkarin Supatrakul
Abdominal cocoon syndrome-a rare culprit behind small bowel ischemia and obstruction: Three case reports

4 June 2025 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
SSSuwan Sanmee
Suwan Sanmee
WVWITCHA VIPUDHAMORN
WITCHA VIPUDHAMORN
PSPawit Sutharat
Pawit Sutharat
ESEkkarin Supatrakul
Ekkarin Supatrakul
KWKraipop Wongwaiyut
Kraipop Wongwaiyut
This case report highlights a rare instance of colonic intussusception mimicking strangulated rectal prolapse in a woman. Initially misdiagnosed with strangulated rectal prolapse, the patient presented with a painful, irreducible rectal mass. Unexpected clinical signs led to further imaging, revealing colonic intussusception with a malignant mass. This underscores the diagnostic challenges of overlapping symptoms and the necessity of thorough examinations to detect subtle anatomical differences. An emergency CT scan showed a prolapsed sigmoid colon prompting a total mesorectal excision and end colostomy due to poor sphincter tone, with positive postoperative results. This case emphasises maintaining a high suspicion for alternative diagnoses in ambiguous rectal masses and advocates for a multidisciplinary approach using advanced imaging when examinations are atypical. An accurate preoperative diagnosis and tailored surgical strategy are crucial for optimal outcomes, highlighting the importance of individualised management in complex colorectal cases.

16 August 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
SSSuwan Sanmee
Suwan Sanmee
WVWITCHA VIPUDHAMORN
WITCHA VIPUDHAMORN
PSPawit Sutharat
Pawit Sutharat
ESEkkarin Supatrakul
Ekkarin Supatrakul
Background: Hemorrhoidal disease, affecting over 20 % of the population, presents management challenges due to its multifaceted nature. While treatments like Micronized Purified Flavonoid Fraction (MPFF) show promise, Aescin's efficacy remains uncertain. This study assesses the combined effectiveness of Aescin with MPFF against MPFF alone in treating Grades 1 and 2 hemorrhoids, focusing on halting bleeding and reducing mass effect. Method: This study recruited patients from the Division of Colorectal Surgery, Chiang Mai University. Patients were randomly assigned to receive MPFF alone or MPFF with Aescin. Outcomes included the duration until bleeding cessation and resolution of mass effect. Results: Of 120 patients randomized to each group, the combination therapy demonstrated superiority in halting bleeding (two days VS four days) and resolving mass effect (four days VS five days) compared to MPFF alone with statistically significant differences. Treatment failure rates were lower in the combination therapy group, with high patient satisfaction. Conclusion: Combining Aescin with MPFF shows promise as a therapeutic approach for Grades 1 and 2 internal hemorrhoids, offering expedited relief from bleeding and mass effect. These findings suggest the need for further research to validate results in larger cohorts and optimize treatment strategies for hemorrhoidal disease. (c) 2024 Asian Surgical Association and Taiwan Society of Coloproctology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).

8 June 2023 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Closed access
PDF file
WVWITCHA VIPUDHAMORN
WITCHA VIPUDHAMORN
SJSunhawit Junrungsee
Sunhawit Junrungsee
WLWorakitti Lapisarepun
Worakitti Lapisarepun
WKWasana Ko-Iam
Wasana Ko-Iam
TSTrichak Sandhu
Trichak Sandhu
ACAnon Chotirosniramit
Anon Chotirosniramit
Witcha VIPUDHAMORN, Sunhawit JUNRUNGSEE*, Worakitti LAPISAREPUN, Wasana KO-IAM, Trichak SANDHU, Anon CHOTIROSNIRAMIT. Ann Hepatobiliary Pancreat Surg 2023;27:S41. https://doi.org/10.14701/ahbps.2023S1.PL-1

30 June 2026 in Annals of Coloproctology
Verified
Journal Article
Open access
WVWITCHA VIPUDHAMORN
WITCHA VIPUDHAMORN
PSPawit Sutharat
Pawit Sutharat
SSSuwan Sanmee
Suwan Sanmee
ESEkkarin Supatrakul
Ekkarin Supatrakul
SJSunhawit Junrungsee
Sunhawit Junrungsee
Purpose: Recurrence after initial control of acute internal hemorrhoidal bleeding remains a common and clinically relevant challenge. Escin, a venotonic and anti-inflammatory compound, may augment the therapeutic effects of micronized purified flavonoid fraction (MPFF). This study aimed to evaluate whether the addition of escin to MPFF reduces recurrence of acute internal hemorrhoidal bleeding.Methods: In this double-blind randomized controlled trial, adults with grade 1 or 2 acute bleeding internal hemorrhoids received MPFF 3,000 mg/day for 7 days in combination with either escin 120 mg/day or a matched placebo. Patients who achieved hemostasis subsequently continued MPFF 1,000 mg/day with escin or placebo for 2 months. The primary endpoint was recurrence within 90 days, defined clinically and confirmed by proctoscopy. Secondary outcomes included time to hemostasis, the Short Health Scale for Hemorrhoids (SHSHD), and safety outcomes.Results: Among the 108 patients who achieved hemostasis, recurrence occurred in 0% vs. 7.84% at 1 month and 7.02% vs. 23.52% at 3 months in the escin and placebo groups, respectively. Combination therapy was associated with a significantly reduced risk of recurrence (hazard ratio, 3.95; P=0.009). Time to bleeding cessation was shorter in the escin group (median, 2 days vs. 4 days; P<0.001). Improvement in SHSHD scores was greater with escin. No adverse events were observed in either group.Conclusion: The combination of escin and MPFF reduces recurrence and accelerates symptom resolution in acute internal hemorrhoidal bleeding, with a favorable safety profile.Trial registration: ClinicalTrials.gov identifier: NCT06748014.